These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32538232)

  • 21. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
    Tan J; Zhou J; Zhao P; Wei J
    Clin Rheumatol; 2012 Aug; 31(8):1169-75. PubMed ID: 22544263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus coinfection in patients treated for chronic hepatitis C: clinical characteristics, risk of reactivation with long-term follow-up, and effectiveness of antiviral therapy.
    Zarębska-Michaluk D; Brzdęk M; Rzymski P; Dobrowolska K; Flisiak R
    Pol Arch Intern Med; 2024 Jan; 134(1):. PubMed ID: 38164525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overt and occult hepatitis B virus infection in adult Sudanese HIV patients.
    Mudawi H; Hussein W; Mukhtar M; Yousif M; Nemeri O; Glebe D; Kramvis A
    Int J Infect Dis; 2014 Dec; 29():65-70. PubMed ID: 25449238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
    Spaan M; Bruce M; Agarwal K; Carey I
    Antivir Ther; 2018; 23(6):539-542. PubMed ID: 30309997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy.
    Majeed NA; Alawad AS; Liem KS; Takyar V; Alter H; Feld JJ; Janssen HLA; Ghany MG
    Dig Dis Sci; 2023 Jul; 68(7):3193-3198. PubMed ID: 37022602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
    Kawagishi N; Suda G; Sakamori R; Matsui T; Onozawa M; Yang Z; Yoshida S; Ohara M; Kimura M; Kubo A; Maehara O; Fu Q; Hosoda S; Tokuchi Y; Suzuki K; Nakai M; Sho T; Morikawa K; Natsuizaka M; Ogawa K; Sakai H; Ohnishi S; Baba M; Takehara T; Sakamoto N
    Sci Rep; 2022 Oct; 12(1):16800. PubMed ID: 36207368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Occult HBV Infection in Patients Infected by HIV or HCV: Comparison between HBV-DNA and Two Assays for HBsAg.
    Meschi S; Mizzoni K; Leoni BD; Galli C; Garbuglia AR; Belladonna S; Girardi E; Maggi F; The Hbsagn Study Group
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients.
    Tseng CW; Liu WC; Ko PH; Chen YC; Tseng KC; Chang TT
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents.
    Wang C; Ji D; Chen J; Shao Q; Li B; Liu J; Wu V; Wong A; Wang Y; Zhang X; Lu L; Wong C; Tsang S; Zhang Z; Sun J; Hou J; Chen G; Lau G
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):132-136. PubMed ID: 27392759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection.
    Jacob R; Danta M
    Expert Opin Pharmacother; 2022 Mar; 23(4):465-472. PubMed ID: 34937470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
    Bersoff-Matcha SJ; Cao K; Jason M; Ajao A; Jones SC; Meyer T; Brinker A
    Ann Intern Med; 2017 Jun; 166(11):792-798. PubMed ID: 28437794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data.
    El Kassas M; Shimakawa Y; Ali-Eldin Z; Funk AL; Wifi MN; Zaky S; El-Raey F; Esmat G; Fontanet A
    Liver Int; 2018 Dec; 38(12):2159-2169. PubMed ID: 29738637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
    J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection.
    Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
    Arch Virol; 1997; 142(3):535-44. PubMed ID: 9349299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India.
    Gupta S; Singh S
    BMC Infect Dis; 2010 Mar; 10():53. PubMed ID: 20205948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.
    Belperio PS; Shahoumian TA; Mole LA; Backus LI
    Hepatology; 2017 Jul; 66(1):27-36. PubMed ID: 28240789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients.
    Lo Re V; Frank I; Gross R; Dockter J; Linnen JM; Giachetti C; Tebas P; Stern J; Synnestvedt M; Localio AR; Kostman JR; Strom BL
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):315-20. PubMed ID: 17159655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents.
    Gutiérrez García ML; Manzano Alonso ML; Ferrer Rosique JÁ; Muñoz Gómez R; Alonso López S; Fernández Álvarez I; Fernández Rodríguez CM
    Rev Esp Enferm Dig; 2019 Feb; 111(2):129-133. PubMed ID: 30421955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.